Aug. 15, 2022 — The Inflation Reduction Act passed last week may represent the best outcome the biopharma industry reasonably could have hoped for at a time when so many in Congress are eager to respond to strong public opinion that prescription prices are too high. The new legislation, which reins in some drug costs […]
Read moreMarch 14, 2016 — The American Medical Association (AMA) as well as Rep. Rosa DeLauro (D-Conn.) and Sen. Al Franken (D-Minn.) are calling for a ban on or restrictions to direct-to-consumer (DTC) drug ads that might result in a dip in drug sales, but also would hurt patients by eliminating the advantages of DTC drug […]
Read moreNov. 9, 2015 – Congress, federal agencies and the media continue to turn up the heat on their examination of drug pricing practices, but the industry is starting to defend itself – with facts. As part of a multi-pronged effort to defend the worth of pharmaceutical companies and their products, the Pharmaceutical Research and Manufacturers […]
Read moreSept. 24, 2015 – Presidential hopeful Hillary Clinton just announced that she would “demand a stop to excessive profiteering and marketing by denying tax breaks for direct-to-consumer [DTC] advertising and demanding that drug companies invest in R&D in exchange for taxpayer support,” according to a briefing released this week by her campaign. Under Clinton’s plan, […]
Read more